Baoguo Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Baoguo Liu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Guanglong Huang
Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
1 shared publication - Jun Pan
AVIC Nanjing Electromechanical Hydraulic Engineering Center, Nanjing, China
1 shared publication - Li Jia
College of Laboratory Medicine, Dalian Medical University, Dalian 116044, 9 Lushunnan Road Xiduan, Dalian, 116044, Liaoning Province, China.
1 shared publication Ling Zhang
Department of Dermatology, Affiliated Hospital of Hebei University of Engineering, Handan, China
1 shared publicationLiu XiaoJun
Nanfang Hospital, Southern Medical University
1 shared publication- Luxiong Fang
Department of Neurosurgery, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Dadao Bei Street, Guangzhou, 510515, P. R. China.
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by XMLink in Annals of Dermatology
- Vol. 30 (5) , 536-543
Gene Expression Patterns of Cutaneous Squamous Cell Carcinoma and Actinic Keratosis: Biomarkers Screening for Skin Disease Diagnosis
Li X, et al. Ann Dermatol. 2018 Oct;30(5):536-543. https://doi.org/10.5021/ad.2018.30.5.536
- 1 January 2018
- Published by XMLink in Annals of Dermatology
- Vol. 30 (5) , 536-543
Open AccessGene Expression Patterns of Cutaneous Squamous Cell Carcinoma and Actinic Keratosis: Biomarkers Screening for Skin Disease Diagnosis
Li X, et al. Ann Dermatol. 2018 Oct;30(5):536-543. https://doi.org/10.5021/ad.2018.30.5.536
- Open Access
- 22 May 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-11
Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell
Malignant melanoma (MM) is one of the high degree of malignancy and early prone to blood and lymph node metastasis. There is not cured for MM. Tan II A has been reported to reduce cancer cell proliferation. But the mechanism by which Tan II A inhibited melanoma growth are not well characterized. We sought to explore the possible mechanism by which Tan II A regulated cell proliferation through autophagy signaling pathway in A375 cells. We tested the effects of Tan II A on melanoma A375, MV3, M14, and other human cell lines including Hacat and HUVEC cells in cell culture model. Cell proliferation was assessed by using methyl thiazol tetrazolium (MTT) assay. Cell migration ability melanoma A375 was monitored by using cell scratch assay. Transwell chamber experimental was performed to assess the effect of Tan II A on A375 melanoma cell invasion ability. The autophagy body was examined by using flow cytometry. The expression of autophagy-associated protein beclin-1 and microtubule-associated protein 1 light chain 3(LC3)-II, as well as phosphatidylinositol 3-kinase(PI3K)、protein kinase B (Akt)、mammalian target of rapamycin (mTOR)、p70S6K1 signaling pathways were detected by using Western blotting. The effects of Tan II A on tumor progression was also examined in melanoma A375 induced tumor in mouse model. We found that Tan IIA inhibited melanoma A375, MV3, and M14 cell proliferation in dose and time dependent manner. Tan II A reduced CXCL12-induced A375 cell invasive ability and migration in a dose dependent manner. Tan IIA promoted autophagic body production and increased autophagy-associated protein beclin-1 and LC3-II expression in A375 cells. However, Tan IIA reduced the phosphorylation of PI3K, P-AKT, P-mTOR, and P-p7036k1. We also confirmed that Tan II A reduced melanoma A375 induced tumor volume and weight in mouse model. We concluded that Tan II A reduced A375 cells proliferation by activation of autophagy production, blocked PI3K- Akt – mTOR - p70S6K1 signaling pathway, increased autophagic related gene beclin-1, LC3-II protein expressions and induced autophagocytosis. Tan II A inhibited melanoma A375 induced tumor development in mouse model.
- 22 May 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-11
Open AccessMechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell
Malignant melanoma (MM) is one of the high degree of malignancy and early prone to blood and lymph node metastasis. There is not cured for MM. Tan II A has been reported to reduce cancer cell proliferation. But the mechanism by which Tan II A inhibited melanoma growth are not well characterized. We sought to explore the possible mechanism by which Tan II A regulated cell proliferation through autophagy signaling pathway in A375 cells. We tested the effects of Tan II A on melanoma A375, MV3, M14, and other human cell lines including Hacat and HUVEC cells in cell culture model. Cell proliferation was assessed by using methyl thiazol tetrazolium (MTT) assay. Cell migration ability melanoma A375 was monitored by using cell scratch assay. Transwell chamber experimental was performed to assess the effect of Tan II A on A375 melanoma cell invasion ability. The autophagy body was examined by using flow cytometry. The expression of autophagy-associated protein beclin-1 and microtubule-associated protein 1 light chain 3(LC3)-II, as well as phosphatidylinositol 3-kinase(PI3K)、protein kinase B (Akt)、mammalian target of rapamycin (mTOR)、p70S6K1 signaling pathways were detected by using Western blotting. The effects of Tan II A on tumor progression was also examined in melanoma A375 induced tumor in mouse model. We found that Tan IIA inhibited melanoma A375, MV3, and M14 cell proliferation in dose and time dependent manner. Tan II A reduced CXCL12-induced A375 cell invasive ability and migration in a dose dependent manner. Tan IIA promoted autophagic body production and increased autophagy-associated protein beclin-1 and LC3-II expression in A375 cells. However, Tan IIA reduced the phosphorylation of PI3K, P-AKT, P-mTOR, and P-p7036k1. We also confirmed that Tan II A reduced melanoma A375 induced tumor volume and weight in mouse model. We concluded that Tan II A reduced A375 cells proliferation by activation of autophagy production, blocked PI3K- Akt – mTOR - p70S6K1 signaling pathway, increased autophagic related gene beclin-1, LC3-II protein expressions and induced autophagocytosis. Tan II A inhibited melanoma A375 induced tumor development in mouse model.
- 10 November 2009
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 98 (1) , 21-30
Involvement of osteopontin as a core protein in craniopharyngioma calcification formation
Matrix proteins are considered to be essential for biomineralization and to be important factors in cranioharyngioma calcification. Osteopontin (OPN) is a noncollagenous, acidic bone-matrix glycoprotein, which binds tightly to hydroxyapatite and appears to form an integral part of the mineralized matrix, probably important to the integrity of cell–matrix interactions. OPN is also a ligand for a cell membrane receptor, CD44v6, which is required for efficient OPN binding. To investigate the role of OPN in craniopharyngioma calcification formation, we studied the involvement of OPN and CD44v6 in craniopharyngiomas. Immunohistochemical staining was used in human craniopharyngiomas to detect the relationship of OPN and degree of calcification, and immunogold localization of OPN was done to identify cell secretory granules. OPN expression was elevated in calcification craniopharyngioma samples. Immunohistochemical staining demonstrated that the OPN expression level was significantly correlated with the degree of calcification (χ2 = 29.987, P < 0.001); meanwhile, immunoelectron microscopy revealed subcellular sites of OPN presenting in epithelial cells, suggesting that the OPN protein is probably synthesized and secreted by stellate reticulum-like cells and ameloblast-like cells. At the same time, OPN expression was paralleled by cell surface reactivity for CD44v6, an OPN functional receptor. These results suggest that OPN is possibly involved as a core protein in the formation of craniopharyngioma calcification.
- 10 November 2009
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 98 (1) , 21-30
Involvement of osteopontin as a core protein in craniopharyngioma calcification formation
Matrix proteins are considered to be essential for biomineralization and to be important factors in cranioharyngioma calcification. Osteopontin (OPN) is a noncollagenous, acidic bone-matrix glycoprotein, which binds tightly to hydroxyapatite and appears to form an integral part of the mineralized matrix, probably important to the integrity of cell–matrix interactions. OPN is also a ligand for a cell membrane receptor, CD44v6, which is required for efficient OPN binding. To investigate the role of OPN in craniopharyngioma calcification formation, we studied the involvement of OPN and CD44v6 in craniopharyngiomas. Immunohistochemical staining was used in human craniopharyngiomas to detect the relationship of OPN and degree of calcification, and immunogold localization of OPN was done to identify cell secretory granules. OPN expression was elevated in calcification craniopharyngioma samples. Immunohistochemical staining demonstrated that the OPN expression level was significantly correlated with the degree of calcification (χ2 = 29.987, P < 0.001); meanwhile, immunoelectron microscopy revealed subcellular sites of OPN presenting in epithelial cells, suggesting that the OPN protein is probably synthesized and secreted by stellate reticulum-like cells and ameloblast-like cells. At the same time, OPN expression was paralleled by cell surface reactivity for CD44v6, an OPN functional receptor. These results suggest that OPN is possibly involved as a core protein in the formation of craniopharyngioma calcification.